Supplementation of nucleoside-nucleotide mixture enhances functional recovery and energy metabolism following long-time hypothermic heart preservation.
BACKGROUND
OG-VI, a well-balanced mixture of nucleoside and nucleotides, has been demonstrated to have a favorable effect on energy metabolism. In this study, we tested the hypothesis that addition of OG-VI to the University of Wisconsin solution can improve the cardiac functional recovery following long-time hypothermic preservation.


METHODS
Forty-two male Wistar rats were randomized into four groups. After 30-min of isolated working heart perfusion, the rat hearts were arrested with St. Thomas cardioplegic solution and preserved at 4 degrees C in saline, OG-VI, UW, and UW+OG-VI, respectively. After 12-h of preservation, the hearts were reperfused for 60-min during which the recovery of cardiac functions were monitored continuously. Myocardial adenine nucleotides were analyzed using high-performance liquid chromomatograph.


RESULTS
In the UW+OG-VI group, the recovery of cardiac output, coronary flow, aortic flow, rate-pressure product, left ventricle stroke volume, and stroke work were significantly higher than other groups (P < 0.05). Furthermore, all phosphate high-energy compounds were significantly higher in the UW+OG-VI group than in the other groups (P < 0.05). Coronary vascular resistance and myocardial wet/dry weight ratio were obviously lower in the UW+OG-VI group, compared to the other groups (P < 0.05).


CONCLUSIONS
Heart function was better recovered when nucleoside-nucleotide mixture was added to UW solution during long-time hypothermic rat heart preservation. The mechanism is not totally clear, but enhancement of high-energy phosphate production is possible.
Xing
Yutong
Y
Department of Thoracic and Cardiovascular Surgery and Regeneration Technology, Graduate School of Medicine, Kochi University, Kochi, Japan.
Gopalrao Rajesh
Katare
K
Suzuki
Ryoko
R
Yamamoto
Morio
M
Rao
Parijatha
P
Sasaguri
Shiro
S
D000241:Adenosine / Q000494:pharmacology; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D015925:Cryopreservation; D004338:Drug Combinations; D004734:Energy Metabolism / Q000187:drug effects*; D005978:Glutathione / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D007328:Insulin / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D009705:Nucleosides / Q000378:metabolism / Q000494:pharmacology*; D009711:Nucleotides / Q000378:metabolism / Q000494:pharmacology*; D019188:Organ Preservation Solutions / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D011887:Raffinose / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function / Q000187:drug effects*; D013997:Time Factors
D004338:Drug Combinations; D007328:Insulin; D009705:Nucleosides; D009711:Nucleotides; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose